Thompson Davis & Co’s Apollo Endosurgery, Inc. APEN Stock Holding History

Thompson Davis & Co’s Portfolio APEN Stock Details APEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-25,000	Closed	-$248K	–	139
2023 Q1	$248K	Sell	25,000 -2,000	-7%	-$19.8K	0.32%	67
2022 Q4	$269K	Sell	27,000 -47,078	-64%	-$351K	0.38%	56
2022 Q3	$408K	Sell	74,078 -3,972	-5%	-$22K	0.55%	34
2022 Q2	$285K	Sell	78,050 -74,271	-49%	-$351K	0.47%	46
2022 Q1	$922K	Sell	152,321 -8,258	-5%	-$50.3K	1.12%	19
2021 Q4	$1.35M	Buy	+160,579	New	+$1.4M	1.13%	12
2018 Q3	$14K	Buy	2,000 +250	+14%	+$1.94K	0.03%	408
2018 Q2	$12K	Buy	1,750 +1,250	+250%	+$7.77K	0.03%	411
2018 Q1	$3K	Buy	500 +250	+100%	+$1.57K	0.01%	552
2017 Q4	$1K	Buy	+250	New	+$1.14K	﹤0.01%	650

Thompson Davis & Co's APEN Position: Q2 2023 in Review

Thompson Davis & Co sold out of Apollo Endosurgery, Inc. (APEN) in Q2 2023, closing a stake of 25,000 shares — an estimated $248K sold.

Thompson Davis & Co first reported a position in APEN in Q4 2017 and held it in 10 quarters. The position peaked at $1.35M in Q4 2021. 0 funds tracked by Wall St. Rank hold APEN as of Q2 2023.

Thompson Davis & Co reported no remaining Apollo Endosurgery, Inc. position as of Q2 2023 after selling out during the quarter.
Thompson Davis & Co sold 25,000 Apollo Endosurgery, Inc. shares in Q2 2023, an estimated $248K.
Thompson Davis & Co first reported a position in Apollo Endosurgery, Inc. in Q4 2017 and held it in 10 quarters.
Thompson Davis & Co's Apollo Endosurgery, Inc. position peaked at $1.35M in Q4 2021.
0 funds tracked by Wall St. Rank held Apollo Endosurgery, Inc. as of Q2 2023.

Based on Thompson Davis & Co's 13F filing for Q2 2023, filed 13 Jul 2023.